Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

effectiveness

It includes: 1. Description of treatment duration and causes of treatment discontinuation. 2. Description of adverse events / safety of the treatments 3. Assessment of patients' survival. 4. Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions. 5. Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases

Time frame: through study completion, an average of 1 years

safety

It includes: 1. Description of treatment duration and causes of treatment discontinuation. 2. Description of adverse events / safety of the treatments 3. Assessment of patients' survival. 4. Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions. 5. Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases

Time frame: through study completion, an average of 1 years